Phase 2 Depression and Anxiety Trial, Recruiting NCT04685148 Sponsor: Vibe G Frøkjær, MD, PhD Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT04685148
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are pregnant with a single baby (not twins or more)
  • People who have previously experienced depression related to pregnancy or the period just after birth
  • People who are between 18 and 45 years old

Who may not be able to join:

  • People experiencing moderate to severe depression that began during the current pregnancy
  • People with serious mental health conditions such as schizophrenia, bipolar disorder, conditions involving psychosis, or severe eating disorders or obsessive-compulsive disorder requiring hospital care
  • People who have previously attempted suicide without having had a depressive episode at that time
  • People who have had, or currently have, a neurological condition such as migraines or epilepsy
  • People with a serious physical illness
  • People who have had, or currently have, cancer
  • People with a history of blood clots in the veins, heart attack, stroke caused by a blood clot, or a clotting disorder, or those identified as having related risk factors following a clotting screen
  • People who have had a blood clot in the leg or lungs during the current pregnancy
  • People who have developed high blood pressure or pre-eclampsia during the current pregnancy
  • People with pre-existing hardening of the arteries, or known heart and circulation risk factors such as diabetes or high blood pressure
  • People with other medical reasons that would make oestrogen treatment unsuitable, such as serious liver problems or severe varicose veins (confirm with trial site)
  • People currently taking psychiatric medications, except for short-term sleep support
  • People who are not fluent in Danish, or who have significant vision or hearing difficulties
  • People with a Body Mass Index (BMI) above 35
  • People currently experiencing problems with alcohol or drug misuse
  • People who experienced very heavy bleeding after delivery (more than 1,500 ml)
  • People whose baby has been seriously ill or has died around the time of birth

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Vibe Gedsø Frøkjær, MD, PhD, Neurobiology Research Unit, copenhagen University hospital, Rigshospitalet, Denmark

Phone: +45 35456714

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Vibe G Frøkjær, MD, PhD
Registry
ClinicalTrials.gov
Start date
3 February 2021
Est. completion
31 December 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Number of participants with Major Depression Disorder

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov